Finanzen von Nexalin Technology Inc (NXL)NXLNexalin Technology Inc

Nexalin Technology, Inc. (NXL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Equipment , accounting for 74.4% of total sales, equivalent to $52.53K. Other significant revenue streams include Licensing Fee and Other. Understanding this composition is critical for investors evaluating how NXL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Nexalin Technology, Inc. maintains a gross margin of 73.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18479.69%, while the net margin is -18412.71%. These profitability ratios, combined with a Return on Equity (ROE) of -240.25%, provide a clear picture of how effectively NXL converts its operational activities into shareholder value.

In the context of the broader market, NXL competes directly with industry leaders such as ADGM and BRTX. With a market capitalization of $1.59M, it holds a significant position in the sector. When comparing efficiency, NXL's gross margin of 73.16% stands against ADGM's N/A and BRTX's 68.13%. Such benchmarking helps identify whether Nexalin Technology, Inc. is trading at a premium or discount relative to its financial performance.

Nexalin's financial performance shows a concerning trend with a gross margin of 73.16% in Q2 2026, but it has consistently reported net income losses, reaching -2,239,170 USD in the same quarter. The company has a forward P/E ratio of 0, indicating no expected earnings growth in the near term.